Quick MRI for follow-up of liver cancer after TACE
Part of Cancer, Digestive system clinical trials.
This study compares a shorter MRI scan to standard imaging for checking if liver cancer has come back after a treatment called TACE. It aims to see if the abbreviated MRI can be just as good but faster and more comfortable for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 85 years old.
- You have liver cancer that cannot be removed by surgery.
- You have already had a treatment called TACE (chemoembolization) for your liver cancer.
- Your portal vein (the main vein to the liver) is open, not blocked, and you do not have fluid in the belly (ascites).
- Your liver function is satisfactory, and you do not have severe kidney problems (GFR 60 or higher).
- You can have an MRI scan safely, without metal implants like pacemakers or cochlear implants, and without a serious allergy to contrast dye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a shorter MRI using a special dye to a CT scan for detecting liver cancer recurrence in people who have been cancer-free for at least two years after surgery or local treatment.
This trial studies a faster MRI scan to help track early liver cancer in people who have cirrhosis and are considered high risk. It may improve how often and how well doctors can look for changes without using longer imaging sessions.
This study tests a new type of MRI that can look at the liver in more detail. It compares images from people with liver cancer and healthy people to see if it can help doctors better understand or detect the disease.
This study looks at ways to improve screening for liver cancer in adults with long-term liver disease. It may help catch liver cancer earlier, which can make treatment easier.
This study compares a shorter, non-contrast MRI and ultrasound to monitor for liver cancer in people with cirrhosis whose ultrasound images aren’t clear enough. It aims to see which method works better and may help you get safer, more reliable follow-up.
This early-stage trial studies a new strategy for hepatocellular carcinoma (a type of liver cancer) in people who are planned to receive TACE, a procedure that delivers treatment through the liver’s blood supply. It aims to test whether targeting a specific cell survival process can improve how well the treatment works and is tolerated.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.